Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas T Ross

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Breast Cancer Research : BCR|March 25, 2009
TLE3 as a candidate biomarker of response to taxane therapySwati A Kulkarni, David G Hicks, Nancy L Watroba, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amidesLing Wei, Yon- Qian Wu, Douglas E Wilkinson, et al.
Clinical Lung Cancer|December 23, 2022
27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer StudyDavid L Saltman, Matthew G Varga, Tyler J Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancerBrian Z Ring, Robert S Seitz, Rod Beck, et al.
Bioorganic & Medicinal Chemistry|October 15, 2003
Synthesis, molecular modeling and biological evaluation of aza-proline and aza-pipecolic derivatives as FKBP12 ligands and their in vivo neuroprotective effectsDouglas E Wilkinson, Bert E Thomas, David C Limburg, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitorsChi Choi, Jia-He Li, Mark Vaal, et al.
Breast Cancer Research : BCR|July 10, 2010
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyJohn M S Bartlett, Jeremy Thomas, Douglas T Ross, et al.
BMC Cancer|March 24, 2010
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrenceDavid G Hicks, Bagi R Janarthanan, Ramya Vardarajan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology studyJohn M S Bartlett, Kenneth J Bloom, Tammy Piper, et al.
BMC Cancer|April 15, 2022
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancerHarsha Ranganath, Amit L Jain, Justin R Smith, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Breast Cancer Research : BCR|March 25, 2009
TLE3 as a candidate biomarker of response to taxane therapySwati A Kulkarni, David G Hicks, Nancy L Watroba, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amidesLing Wei, Yon- Qian Wu, Douglas E Wilkinson, et al.
Clinical Lung Cancer|December 23, 2022
27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer StudyDavid L Saltman, Matthew G Varga, Tyler J Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancerBrian Z Ring, Robert S Seitz, Rod Beck, et al.
Bioorganic & Medicinal Chemistry|October 15, 2003
Synthesis, molecular modeling and biological evaluation of aza-proline and aza-pipecolic derivatives as FKBP12 ligands and their in vivo neuroprotective effectsDouglas E Wilkinson, Bert E Thomas, David C Limburg, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitorsChi Choi, Jia-He Li, Mark Vaal, et al.
Breast Cancer Research : BCR|July 10, 2010
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyJohn M S Bartlett, Jeremy Thomas, Douglas T Ross, et al.
BMC Cancer|March 24, 2010
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrenceDavid G Hicks, Bagi R Janarthanan, Ramya Vardarajan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology studyJohn M S Bartlett, Kenneth J Bloom, Tammy Piper, et al.
BMC Cancer|April 15, 2022
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancerHarsha Ranganath, Amit L Jain, Justin R Smith, et al.
Pageof 4